Tianjin Chase Sun Pharmaceutical Co Ltd
Tianjin Chase Sun Pharmaceutical Co.,Ltd engages in the research and development, production, and sale of various pharmaceutical products in China and internationally. The company provides Chinese medicine formula granules, finished drugs, raw materials, medical devices and excipients, medical and health services, as well as smart supply chain for pharmaceuticals and medical devices. It serves th… Read more
Tianjin Chase Sun Pharmaceutical Co Ltd (300026) - Total Liabilities
Latest total liabilities as of September 2025: CN¥1.96 Billion CNY
Based on the latest financial reports, Tianjin Chase Sun Pharmaceutical Co Ltd (300026) has total liabilities worth CN¥1.96 Billion CNY as of September 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Tianjin Chase Sun Pharmaceutical Co Ltd - Total Liabilities Trend (2006–2024)
This chart illustrates how Tianjin Chase Sun Pharmaceutical Co Ltd's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Tianjin Chase Sun Pharmaceutical Co Ltd Competitors by Total Liabilities
The table below lists competitors of Tianjin Chase Sun Pharmaceutical Co Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Krungthai Card PCL
BK:KTC
|
Thailand | ฿63.35 Billion |
|
Focus Technology Co Ltd
SHE:002315
|
China | CN¥1.64 Billion |
|
Shandong Laiwu Jinlei Wind Power Technology Co Ltd
SHE:300443
|
China | CN¥676.86 Million |
|
CRISIL Limited
NSE:CRISIL
|
India | ₹14.14 Billion |
|
Lightspeed Commerce Inc
NYSE:LSPD
|
USA | $173.40 Million |
|
Anhui Jinhe Industrial Co Ltd
SHE:002597
|
China | CN¥2.71 Billion |
|
Tamburi Investment Partners S.p.A.
LSE:0G9J
|
UK | €543.45 Million |
|
Wuxi Huaguang Boiler Co Ltd
SHG:600475
|
China | CN¥16.50 Billion |
Liability Composition Analysis (2006–2024)
This chart breaks down Tianjin Chase Sun Pharmaceutical Co Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 4.26 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.23 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.18 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Tianjin Chase Sun Pharmaceutical Co Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Tianjin Chase Sun Pharmaceutical Co Ltd (2006–2024)
The table below shows the annual total liabilities of Tianjin Chase Sun Pharmaceutical Co Ltd from 2006 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | CN¥2.37 Billion | -20.24% |
| 2023-12-31 | CN¥2.97 Billion | -28.80% |
| 2022-12-31 | CN¥4.17 Billion | +14.03% |
| 2021-12-31 | CN¥3.65 Billion | +31.11% |
| 2020-12-31 | CN¥2.79 Billion | +105.55% |
| 2019-12-31 | CN¥1.36 Billion | +49.43% |
| 2018-12-31 | CN¥907.61 Million | -1.31% |
| 2017-12-31 | CN¥919.62 Million | -26.00% |
| 2016-12-31 | CN¥1.24 Billion | +5.07% |
| 2015-12-31 | CN¥1.18 Billion | +72.69% |
| 2014-12-31 | CN¥684.85 Million | +32.62% |
| 2013-12-31 | CN¥516.40 Million | +24.38% |
| 2012-12-31 | CN¥415.19 Million | +16.15% |
| 2011-12-31 | CN¥357.47 Million | +96.26% |
| 2010-12-31 | CN¥182.14 Million | +35.02% |
| 2009-12-31 | CN¥134.90 Million | +47.22% |
| 2008-12-31 | CN¥91.63 Million | -19.47% |
| 2007-12-31 | CN¥113.79 Million | +34.91% |
| 2006-12-31 | CN¥84.34 Million | -- |